GlassScriptPhysician profile
Mohammad Abdrabbo
NPI 1104828201
$2,986.40
in general payments reported to CMS, 2019-2025
19 companies · $979 in 2025
The $979 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.47 · 2020: $60.16 · 2022: $396 · 2023: $1,021 · 2024: $516 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $994.03 | 2022-2025 | Rinvoq, Skyrizi, Linzess |
| E.R. Squibb & Sons, L.L.C. | $241.94 | 2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $241.35 | 2020-2025 | Entyvio |
| Janssen Biotech, INC. | $231.98 | 2022-2025 | Tremfya |
| Erbe USA INC | $200.00 | 2023 | Erbe Vio3 |
| Olympus America INC. | $168.96 | 2025 | Single Use Repositionable Clip, Hanarostent Esophagus Tts(Ccc), Olympus |
| Boston Scientific Corporation | $164.51 | 2023-2025 | Axonics, Resolution 360 Clip, Endoarmor |
| Phathom Pharmaceuticals, INC. | $137.97 | 2024 | Voquezna |
| Steris Corporation | $136.55 | 2025 | |
| Genzyme Corporation | $122.92 | 2023 | |
| Madrigal Pharmaceuticals | $115.11 | 2024-2025 | Rezdiffra |
| Celgene Corporation | $74.51 | 2022-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.50 | 2023-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $34.83 | 2025 | Dupixent |
| Pfizer INC. | $20.67 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $16.50 | 2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $14.47 | 2019 | |
| Organon LLC | $13.94 | 2022 | |
| Celltrion USA INC. | $13.66 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Abdrabbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.